These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33733920)

  • 1. Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
    Mott DJ; Shah KK; Ramos-Goñi JM; Devlin NJ; Rivero-Arias O
    Med Decis Making; 2021 Jul; 41(5):584-596. PubMed ID: 33733920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.
    Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W
    Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
    Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
    Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value Set for the EQ-5D-Y-3L in Hungary.
    Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EQ-5D-Y Value Set for Slovenia.
    Prevolnik Rupel V; Ogorevc M;
    Pharmacoeconomics; 2021 Apr; 39(4):463-471. PubMed ID: 33565048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating an EQ-5D-Y-3L Value Set for Brazil.
    Espirito Santo CM; Miyamoto GC; Santos VS; Ben ÂJ; Finch AP; Roudijk B; de Jesus-Moraleida FR; Stein AT; Santos M; Yamato TP
    Pharmacoeconomics; 2024 Sep; 42(9):1047-1063. PubMed ID: 38954389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Like holding the axe on who should live or not': adolescents' and adults' perceptions of valuing children's health states using a standardised valuation protocol for the EQ-5D-Y-3L.
    Åström M; Conte H; Berg J; Burström K
    Qual Life Res; 2022 Jul; 31(7):2133-2142. PubMed ID: 35201557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EQ-5D-Y Value Set for Germany.
    Kreimeier S; Mott D; Ludwig K; Greiner W;
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Valuation Protocol for the EQ-5D-Y-3L.
    Ramos-Goñi JM; Oppe M; Stolk E; Shah K; Kreimeier S; Rivero-Arias O; Devlin N
    Pharmacoeconomics; 2020 Jul; 38(7):653-663. PubMed ID: 32297224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Test-Retest Reliability of EQ-5D-Y-3L Best-Worst Scaling Choices of Adolescents and Adults.
    Xiong X; Dalziel K; Huang L; Rivero-Arias O
    Value Health; 2023 Jan; 26(1):50-54. PubMed ID: 35970707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best-Worst Scaling.
    Dalziel K; Catchpool M; García-Lorenzo B; Gorostiza I; Norman R; Rivero-Arias O
    Pharmacoeconomics; 2020 May; 38(5):499-513. PubMed ID: 31974830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An EQ-5D-Y-3L Value Set for Belgium.
    Dewilde S; Roudijk B; Tollenaar NH; Ramos-Goñi JM
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):169-180. PubMed ID: 36316544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why Do Adults Value EQ-5D-Y-3L Health States Differently for Themselves Than for Children and Adolescents: A Think-Aloud Study.
    Reckers-Droog V; Karimi M; Lipman S; Verstraete J
    Value Health; 2022 Jul; 25(7):1174-1184. PubMed ID: 35168891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valuing EQ-5D-Y: the current state of play.
    Devlin N; Pan T; Kreimeier S; Verstraete J; Stolk E; Rand K; Herdman M
    Health Qual Life Outcomes; 2022 Jul; 20(1):105. PubMed ID: 35794607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Child health valuation protocol for a discrete choice experiment comparing paired comparison and kaizen tasks and estimating US EQ-5D-Y-3L values on an experience scale.
    Jumamyradov M; Craig BM; Rivero-Arias O; Jakubczyk M
    BMJ Open; 2023 Oct; 13(10):e077256. PubMed ID: 37879694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating an EQ-5D-Y-3L Value Set for China.
    Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states.
    Lipman SA; Reckers-Droog VT; Karimi M; Jakubczyk M; Attema AE
    Eur J Health Econ; 2021 Dec; 22(9):1507-1518. PubMed ID: 34611793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.